295 related articles for article (PubMed ID: 37582363)
1. Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.
Cortés-López M; Chamely P; Hawkins AG; Stanley RF; Swett AD; Ganesan S; Mouhieddine TH; Dai X; Kluegel L; Chen C; Batta K; Furer N; Vedula RS; Beaulaurier J; Drong AW; Hickey S; Dusaj N; Mullokandov G; Stasiw AM; Su J; Chaligné R; Juul S; Harrington E; Knowles DA; Potenski CJ; Wiseman DH; Tanay A; Shlush L; Lindsley RC; Ghobrial IM; Taylor J; Abdel-Wahab O; Gaiti F; Landau DA
Cell Stem Cell; 2023 Sep; 30(9):1262-1281.e8. PubMed ID: 37582363
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
3. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
[TBL] [Abstract][Full Text] [Related]
4. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
5. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
6. A variant erythroferrone disrupts iron homeostasis in
Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
[TBL] [Abstract][Full Text] [Related]
7. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
[TBL] [Abstract][Full Text] [Related]
8. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
9. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
10. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
[TBL] [Abstract][Full Text] [Related]
11. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
12.
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
[TBL] [Abstract][Full Text] [Related]
13. m
Cieśla M; Ngoc PCT; Muthukumar S; Todisco G; Madej M; Fritz H; Dimitriou M; Incarnato D; Hellström-Lindberg E; Bellodi C
Mol Cell; 2023 Apr; 83(7):1165-1179.e11. PubMed ID: 36944332
[TBL] [Abstract][Full Text] [Related]
14. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
[TBL] [Abstract][Full Text] [Related]
15. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.
Lieu YK; Liu Z; Ali AM; Wei X; Penson A; Zhang J; An X; Rabadan R; Raza A; Manley JL; Mukherjee S
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930825
[TBL] [Abstract][Full Text] [Related]
16. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.
Qiu J; Zhou B; Thol F; Zhou Y; Chen L; Shao C; DeBoever C; Hou J; Li H; Chaturvedi A; Ganser A; Bejar R; Zhang DE; Fu XD; Heuser M
RNA; 2016 Oct; 22(10):1535-49. PubMed ID: 27492256
[TBL] [Abstract][Full Text] [Related]
17. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
[TBL] [Abstract][Full Text] [Related]
18. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
19. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Jenkins JL; Kielkopf CL
Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations of SUGP1 mimic mutant-SF3B1 splice pattern in lung adenocarcinoma and other cancers.
Alsafadi S; Dayot S; Tarin M; Houy A; Bellanger D; Cornella M; Wassef M; Waterfall JJ; Lehnert E; Roman-Roman S; Stern MH; Popova T
Oncogene; 2021 Jan; 40(1):85-96. PubMed ID: 33057152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]